Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about the potential release of GT20029 on the grey market and concerns about its safety and authenticity. One user advises waiting for the official release by Kintor.

KX-826 is available on Amazon but not shipped to the Netherlands. The user seeks advice on obtaining it in Europe.

KX826 shows promise as a hair loss treatment with a 10% increase in hair count, but concerns about Kintor's marketing practices and the systemic effects of treatments like GT20029 and RU58841 remain. Users express skepticism and hope, with some preferring traditional treatments like finasteride and minoxidil.

The conversation is about experiences with Kintor's KX-826 for hair loss, specifically regarding side effects. Some users reported side effects from grey market versions, questioning their authenticity.

Dr. Kang-Yell Choi's company, CK Regeon, is developing a drug called KY19382 for hair regeneration, which involves creating fine wounds to activate stem cells. The drug is in the formulation development stage, targeting markets like the US and Korea.

The conversation is about selling KY19382 powder, a novel activator of Wnt/β-catenin signaling, and Kolliphor EL liquid for vehicle formulation. The seller offers worldwide shipping.

The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.

PP405 is likely fake, and JXL069 is an unrefined prototype with unknown side effects. It's advised to wait for the official PP405 release.

Selling KY19382 powder, a novel activator of Wnt/β-catenin signaling, and Kolliphor EL liquid for vehicle formulation. KY19382 is a growth agonist.

SCUBE3 is available online but poses risks like tumor promotion and high costs. Users advise against using it due to health concerns and inefficacy as a standalone treatment.

The conversation discusses the sale of a premixed KY19382 solution for research purposes, highlighting previous unsuccessful group buys and the formulation process. Prices and purchasing options for KY19382 solutions and powder are provided.

PP405 is a safer alternative to JXL069 for hair loss treatment because it penetrates the skin effectively and degrades in the blood, avoiding systemic toxicity. JXL069, when forced into the body, can cause dangerous side effects like lactic acidosis due to its inability to degrade safely.

A user received KX-826 instead of RU58841 and is confused about their order. They are asking if others have experienced similar issues.

Kintor changed their KX-826 pictures on Amazon after backlash over fake images. Users are skeptical about the product's effectiveness and trustworthiness, with some preferring finasteride instead.

RT1640, a combination of cyclosporin A, minoxidil, and RT175, is discussed as a potential treatment for hair regrowth and repigmentation. The unique formulation aims to enhance hair follicle growth and restore hair pigment without the negative side effects of immunosuppressants.

The conversation is about the potential availability of GT20029 on the black market and whether users would try it. Participants advise waiting for phase 3 trial results to ensure safety and efficacy.

Kintor edited their Amazon page, removing claims that KX-826 provides "real" visible results from clinical experiments. The discussion includes treatments like Minoxidil, finasteride, and RU58841.

Kintor Pharma has started a Phase II trial in China for GT20029, a potential new treatment for hair loss. Participants are discussing the significance, potential release dates, and comparing it to other treatments and technologies like stem cell hair transplants and SAMIRNA.

The conversation is about sourcing Winlevi (clascoterone) for personal use in the EU. The user is specifically looking for a non-generic version.

The user is frustrated with Koshinemall's disorganized service and delayed shipping of KX-826. They are seeking feedback on whether others have received their KX-826 orders.

The conversation is about a user offering an unopened bottle of KX-826 (0.5%) for hair loss treatment, stating it works well for them. They are selling it at cost without seeking profit.

KX826 is considered a legitimate option for those who cannot use finasteride or dutasteride, but many users report it as ineffective compared to RU58841. RU58841 is favored by some due to anecdotal evidence of effectiveness, despite the lack of published clinical data.

People are discussing the group buy and availability of KX-826 for hair loss treatment, with shipments expected around March-April. There is interest in finding more information and joining future group buys.

The conversation discusses the potential of a new hair loss treatment, GT20029, which targets androgen receptors in the scalp and is in phase 1 trials in China. Users express hope that this treatment will be more effective than current options like Minoxidil and Finasteride.

Koshine KX-826 has different versions, and the green version uses a plant-based carrier that may be less irritating for those sensitive to propylene glycol. Users report irritation with some versions of KX-826.

KX-826 may cause increased hair loss for some users, leading to concerns about its effects. One user reported no issues but also no hair regrowth, only maintenance.

Kintor Pharma completed patient enrollment for a Phase II trial in China for GT20029, a potential new treatment for hair loss. Some believe GT20029 could replace finasteride if effective, while others discuss finasteride's limited efficacy and potential underreported side effects.

KX-826 is undergoing Phase III trials in China as a potential treatment for male pattern baldness, with some users considering it as an alternative or addition to finasteride and dutasteride. Opinions on its effectiveness vary, with some users reporting positive results and others finding it expensive and ineffective.

KOSHINE826 is a new anti-hair loss and hair growth solution that claims to effectively control oil, reduce hair fall, and promote real hair growth. It targets androgenetic alopecia by inhibiting DHT and has shown promising results in clinical trials.

KX-826 users report increased shedding, with some experiencing more shedding at higher concentrations. Users are discussing where to purchase the product.